

Gene therapies are poised to fundamentally and profoundly transform the way thousands of genetic diseases are treated. Gene therapies offer the potential of lifelong benefits for patients who currently depend on frequent medications, surgeries, and comprehensive multidisciplinary care for disease management by addressing the underlying cause of genetic disease.

Despite the promise, our healthcare system has not kept pace with the science. This threatens to prevent patients from getting these transformative therapies.

The Institute for Gene Therapies is bringing together experts from across the healthcare system to advocate for a modernized policy framework that encourages innovations and promotes patient access to the treatments they need. We represent innovators and patients, business leaders and academics working to ensure policies reflect medical advances, creating a new reality for patients.

CORPORATE ADVISORY COUNCIL

The members of our Corporate Advisory Council provide collective input on IGT's priorities and engagement activities.



PATIENT ADVOCACY ADVISORY COUNCIL

IGT works with advocacy organizations focused on improving patient access & outcomes.



- **Khrystal Davis**, Rare Disease Advocate, Mother of son w/SMA, Founder of Texas Rare Alliance
- **Jenn McNary**, Patient Advocate & Consultant, Founder, **One Rare**
- **Jennifer Handt**, Duchenne Parent-Advocate and Founder, **Charlie's Cure**
- **Lauren Holder**, Huntington's Disease Patient Advocate and Producer/Host of **Help 4 HD Live Podcast**
- **Rolf Benirschke**, Survivor and Patient Advocate Crohn's Disease, Ulcerative Colitis, Colorectal & Bladder Cancer

SCIENTIFIC, ACADEMIC & MEDICAL ADVISORY COUNCIL

IGT collaborates with members of the scientific, medical & academic communities with a special interest in gene therapy.

- **Vivian G. Cheung**, MD, Life Sciences Institute, Department of Pediatrics, University of Michigan

